[1]
Kumazawa, Y.; Kawaguchi, K.; Takimoto, H. Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor-α. Curr. Pharm. Des., 2006, 12, 427-429.
[2]
Tracey, K.J.; Cerami, A. Cachectin/tumor necrosis factor and other cytokines in infectious disease. Curr. Opin. Immunol., 1989, 1(3), 454-461.
[3]
Dinarello, C.A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J. Infect. Dis., 1991, 163(6), 1177-1184.
[4]
Feldmann, M.; Brennan, F.M.; Chantry, D.; Haworth, C.; Turner, M.; Abney, E.; Buchan, G.; Barrett, K.; Barkley, D.; Chu, A. Cytokine production in the rheumatoid joint: Implications for treatment. Ann. Rheum. Dis., 1990, 49(Suppl. 1), 480-486.
[5]
Brennan, F.M.; Maini, R.N.; Feldmann, M. TNF α--a pivotal role in rheumatoid arthritis? Br. J. Rheumatol., 1992, 31(5), 293-298.
[6]
Paska, W.; McDonald, K.J.; Croft, M. Studies on type II collagen induced arthritis in mice. Agents Actions, 1986, 18(3-4), 413-420.
[7]
Ellis, J.S.; Chain, B.M.; Cooke, A.; Ibrahim, M.A.; Katz, D.R. Adjuvant composition determines the induction of type II collagen-induced arthritis. Scand. J. Immunol., 1992, 36(1), 49-56.
[8]
Williams, R.O.; Feldmann, M.; Maini, R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA, 1992, 89(20), 9784-9788.
[9]
Breedveld, F.C.; van der Lubbe, P.A. Monoclonal antibody therapy of inflammatory rheumatic diseases. Br. Med. Bull., 1995, 51(2), 493-502.
[10]
Feldmann, M.; Maini, R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol., 2001, 19, 1631-1696.
[11]
Padyukov, L.; Lampa, J.; Heimbürger, M.; Ernestam, S.; Cederholm, T.; Lundkvist, I.; Andersson, P.; Hermansson, Y.; Harju, A.; Klareskog, L.; Bratt, J. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis., 2003, 62(6), 526-529.
[12]
Ranganathan, P. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics, 2005, 6(5), 481-490.
[13]
Ueda, H.; Yamazaki, C.; Yamazaki, M. A hydroxyl group of flavonoids affects oral anti-inflammatory activity and inhibition of systemic tumor necrosis factor-alpha production. Biosci. Biotechnol. Biochem., 2004, 68(1), 119-125.
[14]
Wadsworth, T.L.; McDonald, T.L.; Koop, D.R. Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced signaling pathways involved in the release of tumor necrosis factor-alpha. Biochem. Pharmacol., 2001, 62(7), 963-974.
[15]
Okoko, T.; Oruambo, I.F. Inhibitory activity of quercetin and its metabolite on lipopolysaccharide-induced activation of macrophage U937 cells. Food Chem. Toxicol., 2009, 47(4), 809-812.
[16]
Xagorari, A.; Papapetropoulos, A.; Mauromatis, A.; Economou, M.; Fotsis, T.; Roussos, C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J. Pharmacol. Exp. Ther., 2001, 296(1), 181-187.
[17]
Kotanidou, A.; Xagorari, A.; Bagli, E.; Kitsanta, P.; Fotsis, T.; Papapetropoulos, A.; Roussos, C. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am. J. Respir. Crit. Care Med., 2002, 165(6), 818-823.
[18]
Smolinski, A.T.; Pestka, J.J. Modulation of lipopolysaccharide-induced proinflammatory cytokine production in vitro and in vivo by the herbal constituents apigenin (chamomile), ginsenoside Rb(1) (ginseng) and parthenolide (feverfew). Food Chem. Toxicol., 2003, 41(10), 1381-1390.
[19]
Nicholas, C.; Batra, S.; Vargo, M.A.; Voss, O.H.; Gavrilin, M.A.; Wewers, M.D.; Guttridge, D.C.; Grotewold, E.; Doseff, A.I. Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-κB through the suppression of p65 phosphorylation. J. Immunol., 2007, 179(10), 7121-7127.
[20]
Rogers, J.; Perkins, I.; van Olphen, A.; Burdash, N.; Klein, T.W.; Friedman, H. Epigallocatechin gallate modulates cytokine production by bone marrow-derived dendritic cells stimulated with lipopolysaccharide or muramyldipeptide, or infected with Legionella pneumophila. Exp. Biol. Med., 2005, 230(9), 645-651.
[21]
Bae, H.B.; Li, M.; Kim, J.P.; Kim, S.J.; Jeong, C.W.; Lee, H.G.; Kim, W.M.; Kim, H.S.; Kwak, S.H. The effect of epigallocatechin gallate on lipopolysaccharide-induced acute lung injury in a murine model. Inflammation, 2010, 33(2), 82-91.
[22]
Liu, L.L.; Gong, L.K.; Wang, H.; Xiao, Y.; Wu, X.F.; Zhang, Y.H.; Xue, X.; Qi, X.M.; Ren, J. Baicalin inhibits macrophage activation by lipopolysaccharide and protects mice from endotoxin shock. Biochem. Pharmacol., 2008, 75(4), 914-922.
[23]
Wan, J.Y.; Gong, X.; Zhang, L.; Li, H.Z.; Zhou, Y.F.; Zhou, Q.X. Protective effect of baicalin against lipopolysaccharide/D-galactosamine-induced liver injury in mice by up-regulation of heme oxygenase-1. Eur. J. Pharmacol., 2008, 587(1-3), 302-308.
[24]
Kawaguchi, K.; Kikuchi, S.; Hasegawa, H.; Maruyama, H.; Morita, H.; Kumazawa, Y. Suppression of lipopolysaccharide-induced tumor necrosis factor-release and liver injury in mice by naringin. Eur. J. Pharmacol., 1999, 368, 245-250.
[25]
Kawaguchi, K.; Kikuchi, S.; Hasunuma, R.; Maruyama, H.; Ryll, R.; Kumazawa, Y. Suppression of infection-induced endotoxin shock in mice by a citrus flavanone naringin. Planta Med., 2004, 70, 17-22.
[26]
Kawaguchi, K.; Maruyama, H.; Kometani, T.; Kumazawa, Y. Suppression of collagen-induced arthritis by oral administration of the Citrus flavonoid hesperidin. Planta Med., 2006, 72, 477-479.
[27]
Kawaguchi, K.; Maruyama, H.; Hasunuma, R.; Kumazawa, Y. Suppression of inflammatory responses after onset of collagen-induced arthritis in mice by oral administration of the citrus flavanone naringin. Immunopharmacol. Immunotoxicol., 2011, 33, 723-729.
[28]
Terao, J. Dietary flavonoids as antioxidants in vivo: conjugated metabolites of (-)-epicatechin and quercetin participate in antioxidative defense in blood plasma. J. Med. Invest., 1999, 46(3-4), 159-168.
[29]
Terao, J.; Murota, K.; Kawai, Y. Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo. Food Funct., 2011, 2(1), 11-17.
[30]
Kamada, C.; Mukai, R.; Kondo, A.; Sato, S.; Terao, J. Effect of quercetin and its metabolite on caveolin-1 expression induced by oxidized LDL and lysophosphatidylcholine in endothelial cells. J. Clin. Biochem. Nutr., 2016, 58(3), 193-201.
[31]
Conquer, J.A.; Maiani, G.; Azzini, E.; Raguzzini, A.; Holub, B.J. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr., 1998, 128(3), 593-597.
[32]
Egert, S.; Bosy-Westphal, A.; Seiberl, J.; Kürbitz, C. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br. J. Nutr., 2009, 102(7), 1065-1074.
[33]
Heinz, S.A.; Henson, D.A.; Nieman, D.C.; Austin, M.D.; Jin, F. A 12-week supplementation with quercetin does not affect natural killer cell activity, granulocyte oxidative burst activity or granulocyte phagocytosis in female human subjects. Br. J. Nutr., 2010, 104(6), 849-857.
[34]
Bae, S.C.; Jung, W.J.; Lee, E.J.; Yu, R.; Sung, M.K. Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients. J. Am. Coll. Nutr., 2009, 28(1), 56-62.
[35]
Lesser, S.; Cermak, R.; Wolffram, S. The fatty acid pattern of dietary fat influences the oral bioavailability of the flavonol quercetin in pigs. Br. J. Nutr., 2006, 96(6), 1047-1052.
[36]
Sugiyama, T.; Kawaguchi, K.; Dobashi, H.; Miyake, R.; Kaneko, M.; Kumazawa, Y. Quercetin but not luteolin suppresses the induction of lethal shock upon infection of mice with Salmonella typhimurium. FEMS Immunol. Med. Microbiol., 2008, 53(3), 306-313.
35
7